Bifemelane

Bifemelane

Bifemelane
Systematic (IUPAC) name
N-methyl-4-[2-(phenylmethyl)phenoxy]butan-1-amine
Clinical data
AHFS/Drugs.com
Legal status
?
Identifiers
CAS number  YesY
ATC code N06
PubChem
ChemSpider  YesY
UNII  YesY
ChEMBL  N
Chemical data
Formula C18H23NO 
Mol. mass 269.381 g/mol
 N   

Bifemelane (Alnert, Celeport) is a pharmaceutical drug used in the treatment of senile dementia in Japan.[1] It has nootropic, neuroprotective, and antidepressant effects, and acts through the cholinergic system in the brain.[2][3][4] Bifemelane is also useful for the treatment of glaucoma.[5]

See also

References

  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265.  
  2. ^ Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research 24 (4): 409–14.  
  3. ^ Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology 72 (1): 57–65.  
  4. ^ Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology 72 (6): 394–7.  
  5. ^ Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics 18 (1): 106–13.